<DOC>
	<DOCNO>NCT01235975</DOCNO>
	<brief_summary>This study evaluate immunogenicity safety meningococcal conjugate vaccine GSK 134612 give single dose healthy adult 56 year old compare meningococcal polysaccharide vaccine MencevaxACWYTM .</brief_summary>
	<brief_title>Immunogenicity Safety Study GSK Biologicals ' Meningococcal Vaccine Given One Dose Healthy Subjects Above 56 Years</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol A male female 56 year age old time vaccination . Written inform consent obtain subject . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define current tubal ligation , hysterectomy , ovariectomy postmenopause . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Concurrent participation another clinical study , time study period , subject expose investigational noninvestigational product . Extended administration immunosuppressant immunemodifying drug within six month prior vaccination . Inhaled topical steroid allow . Any contraindication intramuscular /or subcutaneous injection . Planned administration/administration vaccine foreseen study protocol within 30 day prior vaccination end 30 day vaccination . ( Vaccination inactivate influenza vaccine , include H1N1 , allow time study per local recommendation ) . Previous vaccination meningococcal serogroups A , C , W135 Y polysaccharide vaccine within 5 year prior vaccination . Previous vaccination time meningococcal serogroups A , C , W135 Y polysaccharide conjugate vaccine . Previous vaccination tetanus toxoid contain vaccine within 5 year prior vaccination . History meningococcal disease due serogroups A , C , W135 Y . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine . History neurological disorder seizures History GuillainBarre syndrome . Acute ( active ) clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination preexist laboratory screening test . Acute disease and/or fever time enrolment . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine/product plan administration study period . Pregnant lactate female . Current chronic alcohol consumption and/or drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>56 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Meningococcal Vaccines</keyword>
	<keyword>serogroups A , C , W-135 Y</keyword>
	<keyword>meningococcal disease</keyword>
	<keyword>meningococcal conjugate vaccine</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>